LEVODRI-25
LEVODRI-25 is a pharmaceutical tablet formulation containing Levosulpiride 25 mg as its active pharmaceutical ingredient. The product is listed in the Suprimeda portfolio under the Anti-Emetics & Antinauseants category and is formulated as an oral tablet dosage form. Levosulpiride is described in the supplied product information as a prokinetic and antiemetic pharmaceutical agent. The formulation provides a defined 25 mg strength of Levosulpiride in each tablet, offering a clearly identified pharmaceutical dosage form for professional healthcare and institutional requirements.
For B2B pharmaceutical identification, relevant product descriptors include Levosulpiride 25 mg tablets, Levosulpiride tablets, antiemetic tablets, prokinetic tablets, Levosulpiride formulation and pharmaceutical tablets. The displayed carton specifies a pack size of 10 × 10 tablets, with the tablets supplied in a blister-pack presentation.
Everything You, Need to Know
LEVODRI-25 is presented in a blister-pack format, with the product carton showing a packaging size of 10 × 10 tablets.
LEVODRI-25 is available as an oral tablet formulation containing 25 mg of Levosulpiride per tablet.
LEVODRI-25 contains Levosulpiride 25 mg as its active pharmaceutical ingredient and is formulated as a tablet. This composition is confirmed in the Suprimeda product document.